<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109313</article-id><article-id pub-id-type="publisher-id">ACM-37765</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_57933854.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  新辅助化疗对194例局部晚期宫颈癌患者疗效观察及预后分析
  The Effect of Neoadjuvant Chemotherapy in 194 Patients with Locally Advanced Cervical Cancer and Prognostic Analysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>宁</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>贝贝</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>利英</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>蓁</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蒋</surname><given-names>长青</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院妇科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2087</fpage><lpage>2094</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨新辅助化疗(Neoadjuvant chemotherapy, NACT)联合手术治疗对IB2和IIA2期局部晚期宫颈癌患者的疗效及生存预后情况。方法：收集2006年9月~2015年5月于青岛大学附属医院妇科接受治疗的IB2和IIA2期局部晚期宫颈癌患者，NACT联合手术治疗131例，直接手术(RH) 63例，观察新辅助化疗的近期疗效，并对两组患者术后生存情况进行对照分析。结果：宫颈鳞癌患者近期有效率74.55%，非鳞癌近期有效率33.33%，差异有统计学意义；低分化、中分化及高分化患者近期有效率分别为79.49%、62.5%、50%，差异有统计学意义。NACT组1年、3年、5年OS分别为98.5%、93.1%、87.6%，RH组患者1年、3年、5年OS分别为96.8%、85.5%、78.7%，两组5年OS差异有统计学意义(P = 0.036)。将NACT组患者再次分为近期有效者与无效者，两组患者5年OS分别为93%、77.3%，有统计学差异(P = 0.006)；NACT有效者与无效者5年DFS分别为90.9%、76.9%，有统计学差异(P = 0.041)。结论：宫颈鳞癌患者及组织分化较低的患者对NACT更为敏感；NACT可以提高局部晚期宫颈癌患者的远期生存率；相对于NACT无效者，NACT有效者可延长LACC患者的总生存期和无瘤生存期。
    Objective: To investigate the efficacy and survival prognosis of neoadjuvant chemotherapy (NACT) combined with surgical treatment for patients with stage IB2 and IIA2 locally advanced cervical cancer. Methods: Collect IB2 and IIA2 locally advanced cervical cancer patients treated in the Department of Gynecology, Qingdao University Affiliated Hospital from September 2006 to May 2015. 131 cases of NACT combined with surgery and 63 cases of direct surgery (RH) were collected. Neoadjuvant chemotherapy was observed. After the short-term curative effect, the survival situation of the two groups of patients was compared and analyzed. Results: The short-term effective rate for patients with cervical squamous cell carcinoma was 74.55%, and the short-term effective rate for non-squamous cell carcinoma was 33.33%. The difference was statistically significant. The short-term effective rates for poorly differentiated, moderately differentiated, and well-differentiated patients were 79.49%, 62.5%, and 50%, respectively. The difference was statistically significant. The 1-year, 3-year, and 5-year OS of the NACT group were 98.5%, 93.1%, and 87.6%, respectively. The 1-year, 3-year, and 5-year OS of the RH group were 96.8%, 85.5%, and 78.7%, respectively. The 5-year OS difference between the two groups was statistically significant (P = 0.036). The patients in the NACT group were divided into the effective and ineffective patients again. The 5-year OS of the two groups was 93% and 77.3% respectively, which was statistically different (P = 0.006); the 5-year DFS of the effective and ineffective NACT patients was 90.9% and 76.9%, respectively, there is a statistical difference (P = 0.041). Conclusion: Cervical squamous cell carcinoma patients and patients with low tissue differentiation are more sensitive to NACT; NACT can improve the long-term survival rate of locally advanced patients; compared with those who had no NACT, those who had NACT could prolong the total survival and tumor-free survival of LACC patients. 
  
 
</p></abstract><kwd-group><kwd>新辅助化疗，局部晚期宫颈癌，直接手术，近期疗效，生存预后, Neoadjuvant Chemotherapy</kwd><kwd> Locally Advanced Cervical Cancer</kwd><kwd> Direct Surgery</kwd><kwd> Short-Term Efficacy</kwd><kwd> Survival Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨新辅助化疗(Neoadjuvant chemotherapy, NACT)联合手术治疗对IB2和IIA2期局部晚期宫颈癌患者的疗效及生存预后情况。方法：收集2006年9月~2015年5月于青岛大学附属医院妇科接受治疗的IB2和IIA2期局部晚期宫颈癌患者，NACT联合手术治疗131例，直接手术(RH) 63例，观察新辅助化疗的近期疗效，并对两组患者术后生存情况进行对照分析。结果：宫颈鳞癌患者近期有效率74.55%，非鳞癌近期有效率33.33%，差异有统计学意义；低分化、中分化及高分化患者近期有效率分别为79.49%、62.5%、50%，差异有统计学意义。NACT组1年、3年、5年OS分别为98.5%、93.1%、87.6%，RH组患者1年、3年、5年OS分别为96.8%、85.5%、78.7%，两组5年OS差异有统计学意义(P = 0.036)。将NACT组患者再次分为近期有效者与无效者，两组患者5年OS分别为93%、77.3%，有统计学差异(P = 0.006)；NACT有效者与无效者5年DFS分别为90.9%、76.9%，有统计学差异(P = 0.041)。结论：宫颈鳞癌患者及组织分化较低的患者对NACT更为敏感；NACT可以提高局部晚期宫颈癌患者的远期生存率；相对于NACT无效者，NACT有效者可延长LACC患者的总生存期和无瘤生存期。</p></sec><sec id="s2"><title>关键词</title><p>新辅助化疗，局部晚期宫颈癌，直接手术，近期疗效，生存预后</p></sec><sec id="s3"><title>The Effect of Neoadjuvant Chemotherapy in 194 Patients with Locally Advanced Cervical Cancer and Prognostic Analysis</title><p>Ning Guo<sup>1</sup>, Beibei Li<sup>1</sup>, Liying Huang<sup>2</sup>, Zhen Wang<sup>2*</sup>, Changqing Jiang<sup>2</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/33-1571561x5_hanspub.png" /></p><p>Received: Sep. 1<sup>st</sup>, 2020; accepted: Sep. 16<sup>th</sup>, 2020; published: Sep. 23<sup>rd</sup>, 2020</p><p><img src="//html.hanspub.org/file/33-1571561x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the efficacy and survival prognosis of neoadjuvant chemotherapy (NACT) combined with surgical treatment for patients with stage IB2 and IIA2 locally advanced cervical cancer. Methods: Collect IB2 and IIA2 locally advanced cervical cancer patients treated in the Department of Gynecology, Qingdao University Affiliated Hospital from September 2006 to May 2015. 131 cases of NACT combined with surgery and 63 cases of direct surgery (RH) were collected. Neoadjuvant chemotherapy was observed. After the short-term curative effect, the survival situation of the two groups of patients was compared and analyzed. Results: The short-term effective rate for patients with cervical squamous cell carcinoma was 74.55%, and the short-term effective rate for non-squamous cell carcinoma was 33.33%. The difference was statistically significant. The short-term effective rates for poorly differentiated, moderately differentiated, and well-differentiated patients were 79.49%, 62.5%, and 50%, respectively. The difference was statistically significant. The 1-year, 3-year, and 5-year OS of the NACT group were 98.5%, 93.1%, and 87.6%, respectively. The 1-year, 3-year, and 5-year OS of the RH group were 96.8%, 85.5%, and 78.7%, respectively. The 5-year OS difference between the two groups was statistically significant (P = 0.036). The patients in the NACT group were divided into the effective and ineffective patients again. The 5-year OS of the two groups was 93% and 77.3% respectively, which was statistically different (P = 0.006); the 5-year DFS of the effective and ineffective NACT patients was 90.9% and 76.9%, respectively, there is a statistical difference (P = 0.041). Conclusion: Cervical squamous cell carcinoma patients and patients with low tissue differentiation are more sensitive to NACT; NACT can improve the long-term survival rate of locally advanced patients; compared with those who had no NACT, those who had NACT could prolong the total survival and tumor-free survival of LACC patients.</p><p>Keywords:Neoadjuvant Chemotherapy, Locally Advanced Cervical Cancer, Direct Surgery, Short-Term Efficacy, Survival Prognosis</p><disp-formula id="hanspub.37765-formula32"><graphic xlink:href="//html.hanspub.org/file/33-1571561x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/33-1571561x8_hanspub.png" /> <img src="//html.hanspub.org/file/33-1571561x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>宫颈癌是目前全球女性最常见的恶性肿瘤之一，居女性恶性肿瘤的第三位。我国每年新发病例达13.15万，死亡人数每年可达5.3万 [<xref ref-type="bibr" rid="hanspub.37765-ref1">1</xref>]。由于健康筛查意识薄弱，大部分患者在就诊时即已发展为局部晚期宫颈癌(locally advanced cervical cancer, LACC)。因其具有肿块大，淋巴转移率高、进展快等高危因素，预后较差。目前，局部晚期宫颈癌治疗方式的选择仍存在较大争议 [<xref ref-type="bibr" rid="hanspub.37765-ref2">2</xref>]。由于全球放疗设备及技术水平差异较大及放疗对年轻患者生殖功能损伤较大等因素，新辅助化疗(NACT)加根治性手术(RS)的治疗模式已被大部分发展中国家地区引入临床实践 [<xref ref-type="bibr" rid="hanspub.37765-ref3">3</xref>]。新辅助化疗可有效缩小肿瘤，消除巨大肿瘤的远处微转移，但其对患者近期疗效及远期预后的影响仍是目前研究的热点。本文旨在探讨新辅助化疗联合根治性手术对LACC患者的临床疗效及生存预后影响。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>回顾性研究2006年9月~2015年5月于青岛大学附属医院妇科接受治疗的IB2和IIA2期(按照FIGO 2009分期标准 [<xref ref-type="bibr" rid="hanspub.37765-ref4">4</xref>])局部晚期宫颈癌患者210例，其中194例获得完整随访资料，应用新辅助化疗联合根治性手术患者131例，直接行根治性手术患者63例。随访结束时间为2020年5月。</p><p>纳入标准：1) 组织学确诊为宫颈癌：鳞癌、腺癌、腺鳞癌；2) FOGO临床分期(2009年分期标准)为IB2及IIA2；3) 我院初诊并于我院定期复查者。</p><p>排除标准：1) 转移性宫颈癌或合并其他部位恶性肿瘤患者；2) 一般情况差，合并严重内科疾病或不能耐受手术的患者；3) 依从性差，未定期复查的患者。</p></sec><sec id="s6_2"><title>2.2. 数据采集</title><p>纳入研究患者的发病年龄等基本信息及体格检查情况：妇科查体、病理诊断(肿瘤分化类型、大小、浸润深度、手术切缘是否有癌细胞等)、盆腹腔CT (或PET-CT)、磁共振、血常规、生化指标等。本研究已获取青岛大学附属医院伦理委员会批准，所有患者均签署知情同意。</p></sec><sec id="s6_3"><title>2.3. 治疗方法</title><p>NACT组：采用以铂类为基础的化疗方案，每3周为一个疗程，根据患者肿瘤缩减情况行1~3疗程NACT，并于末次化疗结束后3周内行宫颈癌根治性手术；直接手术组：直接行宫颈癌根治性手术。宫颈癌根治性手术：广泛性全子宫 + 盆腔淋巴结清扫及/或腹主动脉淋巴结清扫/活检术 + 双侧附件切除或双侧输卵管切除术及卵巢移位术(两组患者均根据患者病理类型、年龄及生育要求决定是否保留卵巢)。对术后病理发现分化较差、有盆腔淋巴结转移、宫旁浸润、宫颈间质深浸润及脉管癌栓等高危病理因素的患者，术后给予追加化疗或放疗等辅助治疗。</p></sec><sec id="s6_4"><title>2.4. 新辅助化疗近期疗效评价</title><p>NACT组患者在结束先期化疗后，行根治性手术前结合辅助检查及妇科检查，按照WHO实体肿瘤疗效评估标准 [<xref ref-type="bibr" rid="hanspub.37765-ref5">5</xref>] 进行分级，完全缓解(CR)：肿瘤病灶完全消失；部分缓解(PR)：肿瘤双径乘积之和减少 ≥ 50%；稳定(SD)：介于PR与PD之间；进展(PD)：肿瘤双径乘积之和增加25%或出现新的病灶。CR与PR认为NACT近期有效，SD与PD认为NACT无效。总生存期(OS)：定义为开始第1次NACT的时间到因该疾病死亡的时间或随访截止的时间；无瘤生存期(DFS)：定义为手术日期开始到肿瘤复发或随访截止的时间。</p></sec><sec id="s6_5"><title>2.5. 统计方法</title><p>数据应用SPSS 26.0进行统计学分析，定量资料采用均数和标准差描述，分类数据采用例数或率进行描述，采用卡方检验；两组计量资料比较采用两个独立样本比较的Wilcoxon秩和检验，两组率或构成比比较采用χ2检验。生存分析采用Kaplan-Meier方法，两组生存率比较采用Log-rank检验。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般临床资料</title><p>对两组患者一般临床资料进行比较。NACT组平均年龄46.2 &#177; 7.56岁，RH组平均年龄47.00 &#177; 8.89岁，两组LACC患者在年龄、病理类型、组织分级、肿瘤直径等均无统计学差异(P &gt; 0.05)，具有可比性。</p></sec><sec id="s7_2"><title>3.2. 近期疗效评估</title><p>在131例患者中，NACT的总体有效率66.41%，有效者87例，包括CR 10例(7.63%)，PR 77例(58.78%)，无效者44例，无一例发生SD。对NACT近期疗效进行单因素分析发现，患者的年龄、FIGO分期、化疗前肿瘤最大直径及化疗的给药途径与NACT近期疗效不相关(P &gt; 0.05)。研究发现，鳞癌患者110例(82例有效，29例无效)，腺癌患者19例(5例有效，14例无效)，腺鳞癌患者2例(均无效)，P &lt; 0.001 &lt; 0.05，差异有统计学意义，病理类型与LACC患者的NACT疗效相关。其中鳞癌有效率可达74.55%，考虑鳞癌对化疗的敏感性更高。同时，低分化(G3)的LACC患者NACT有效率为79.49%，中分化(G2)有效率为62.5%，高分化(G1)的病理类型对新辅助化疗有效率相对较低，差异有统计学意义(P = 0.018 &lt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Analysis of short-term efficacy of NAC</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >分类</th><th align="center" valign="middle"  rowspan="2"  >N</th><th align="center" valign="middle"  colspan="4"  >疗效</th><th align="center" valign="middle"  rowspan="2"  >有效率(%)</th><th align="center" valign="middle"  rowspan="2"  >统计量</th><th align="center" valign="middle"  rowspan="2"  >P</th></tr></thead><tr><td align="center" valign="middle" >CR</td><td align="center" valign="middle" >PR</td><td align="center" valign="middle" >SD</td><td align="center" valign="middle" >PD</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤40</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >48.28</td><td align="center" valign="middle" >6.706</td><td align="center" valign="middle" >0.082</td></tr><tr><td align="center" valign="middle" >41~50</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >70.00</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >51~60</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >68.42</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;61</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >FIGO分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IB2</td><td align="center" valign="middle" >88</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >65.91</td><td align="center" valign="middle" >0.163</td><td align="center" valign="middle" >0.870</td></tr><tr><td align="center" valign="middle" >IIA2</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >67.44</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病理类型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >鳞癌</td><td align="center" valign="middle" >110</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >74.55</td><td align="center" valign="middle" >19.490</td><td align="center" valign="middle" >＜0.001</td></tr><tr><td align="center" valign="middle" >腺癌</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >33.33</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >腺鳞癌</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >分化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >GI</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >50.00</td><td align="center" valign="middle" >8.049</td><td align="center" valign="middle" >0.018</td></tr><tr><td align="center" valign="middle" >G2</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >62.50</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >G3</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >79.49</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿块直径</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤5 cm</td><td align="center" valign="middle" >112</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >64.29</td><td align="center" valign="middle" >0.934</td><td align="center" valign="middle" >0.350</td></tr><tr><td align="center" valign="middle" >&gt;5 cm</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >78.95</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >给药途径</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >动脉介入</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >71.60</td><td align="center" valign="middle" >1.104</td><td align="center" valign="middle" >0.269</td></tr><tr><td align="center" valign="middle" >静脉滴注</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >58.00</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. NACT近期疗效分析</p></sec><sec id="s7_3"><title>3.3. 生存预后</title><sec id="s7_3_1"><title>3.3.1. NACT对生存预后的影响</title><p>纳入研究的194例LACC患者均获得严密随访，平均随访79.5 (4~157)个月，NACT患者1年、3年、5年OS分别为98.5%、93.1%、87.6%，RH患者1年、3年、5年OS分别为96.8%、85.5%、78.7%，两组5年OS差异有统计学意义(如图1，P = 0.036)。NACT患者1年、3年、5年DFS分别为95.4%、87.6%、86.1%，RH (直接手术)组患者1年、3年、5年DFS分别为93.6%、78.5%、76.3%，两者5年DFS差无统计学意义(如图2，P = 0.537)。</p><p>图1. 总生时间(月)</p><p>图2. 无瘤生存时间(月)</p></sec><sec id="s7_3_2"><title>3.3.2. NACT近期疗效对生存预后的影响</title><p>纳入NACT组的131例患者中5年累计死亡18例(有效组7例，无效组11例)，5年累计复发18例(有效组8例，无效组10例)。采用Log-Rank法分析NACT近期疗效与OS及DFS之间的关系，结果显示：NACT有效者5年OS为93%显著高于无效者77.3%，有统计学差异(如图3，P = 0.006)。NACT有效者5年DFS为90.9%显著高于无效者76.9%，有统计学差异(如图4，P = 0.041)。表明NACT有效者可延长总体生存期及无瘤生存期。</p><p>图3. 总生时间(月)</p><p>图4. 无瘤生存时间(月)</p></sec></sec></sec><sec id="s8"><title>4. 讨论</title><p>近年来，随着人们生活方式及社会环境的改变，全球宫颈癌的发病率呈年轻化趋势 [<xref ref-type="bibr" rid="hanspub.37765-ref6">6</xref>]，在发展中国家仍处于持续高发状态。对于肿块直径 &gt; 4 cm的IB2和IIA2期局部晚期宫颈癌(FIGO2009年标准)，目前NCCN指南认为同步放化疗(CCRT)可作为其一线治疗方案，但当放疗剂量达到6 &gt; 10 Gy时，卵巢将被永久性破坏，阴道上皮纤维化，进而形成阴道挛缩，与新辅助化疗相比较，对直肠、膀胱和阴道的毒性反应更高 [<xref ref-type="bibr" rid="hanspub.37765-ref7">7</xref>]。上世纪80年代新辅助化疗理论的提出开辟了LACC的治疗新模式，NACT理论认为：化疗可有效缩小肿瘤体积，增加手术机会，同时抑制或消灭全身可能存在的微转移灶，并防止肿瘤远处转移。NACT的临床研究与应用已有20余年的历史，其显著的近期疗效增加了LACC患者手术机会，降低术后高危病理因素的发生。但远期生存情况是否获益仍是目前争议的焦点。</p><p>宫颈癌的病理类型以鳞癌居多，约占我国宫颈癌的80%~85%。本研究结果表明，鳞癌患者行新辅助化疗的近期有效率高达74.55%，显著高于非鳞癌患者，差异有统计学意义(P &lt; 0.001)。有研究表明 [<xref ref-type="bibr" rid="hanspub.37765-ref8">8</xref>]，与其他类型相比，鳞癌对以铂类为基础的化疗更敏感，具有更高的缓解率，这与本研究结果相一致。一项关于不同组织类型宫颈癌对新辅助化疗反应性的荟萃分析 [<xref ref-type="bibr" rid="hanspub.37765-ref9">9</xref>] 同样表明，与非鳞癌相比，鳞癌患者对化疗的短期反应率更高，且可获得更好的5年总生存期和无瘤生存期。此外，本研究发现对新辅助化疗，组织分化差的LACC患者具有更高的临床有效率(P = 0.018)，这表明组织分化差的患者可能对化疗更敏感。但也有研究表明，肿瘤分化良好的LACC患者较分化差的患者对新辅助化疗更敏感 [<xref ref-type="bibr" rid="hanspub.37765-ref10">10</xref>]。这一结果的出现可能与化疗方案及样本量较小有关，仍有待于开展更大样本及更细化的临床研究。</p><p>临床大数据研究显示，2004~2017年我国术前NACT的应用率随年份呈线性升高 [<xref ref-type="bibr" rid="hanspub.37765-ref11">11</xref>]，至今一直维持在较高的水平。NACT能否延长LACC患者的生存时间是目前研究的重点。Yin [<xref ref-type="bibr" rid="hanspub.37765-ref12">12</xref>] 等人对476例IB2~IIB期患者进行回顾性分析，同时比较了3种治疗方式对宫颈癌患者的生存影响，研究发现NACT组、直接手术组、同步放化疗组5年OS分别为88.67%、80.21%、64.37% (P &lt; 0.001)，5年DFS分别为85%、77.44%、52.94% (P &lt; 0.001)，这一研究认为NACT可提高LACC患者的生存获益。本研究对194例LACC患者进行的随访结果显示NACT与RH组5年OS分别为87.6%和78.7% (P &lt; 0.05)，与上述观点相一致。</p><p>另有研究表明 [<xref ref-type="bibr" rid="hanspub.37765-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.37765-ref14">14</xref>]，与直接手术患者相比较，NACT增加了肿瘤切除率，降低局部和远处复发率及淋巴结转移率，提高患者的OS及DFS。本研究中NACT组患者1年、3年、5年DFS分别为95.4%、87.6%、86.1%，RH组患者1年、3年、5年DFS分别为93.6%、78.5%、76.3%，两组差异虽无统计学意义，但可以看出，NACT组患者1年、3年、5年的无瘤生存率更高。我们认为，NACT可以提高患者的远期生存情况，这可能与化疗后肿瘤体积缩小导致肿瘤负荷减少，微小病灶被杀灭及高危病理患者术后追加放化疗等辅助治疗相关。一项日本的III期随机实验结果显示，NACT组的5年总生存率为70.0%，RH组为74.4% (P = 0.85)，远期生存无明显获益，但术后NACT组术后接受放化疗的患者显着低于RH组(P = 0.015) [<xref ref-type="bibr" rid="hanspub.37765-ref15">15</xref>]。</p><p>目前，NACT的近期有效情况被认为是影响其远期预后的重要因素 [<xref ref-type="bibr" rid="hanspub.37765-ref16">16</xref>]。本研究中NACT有效者的5年OS及DFS分别为93%、90.9%；无效者5年OS及DFS分别为76.9%、77.3%，差异均有统计学意义。表明NACT有效者的远期生存及无瘤生存期显著高于NACT无效者。多项研究同样证实，NACT近期有效者可获得更好的生存预后 [<xref ref-type="bibr" rid="hanspub.37765-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.37765-ref18">18</xref>]。</p></sec><sec id="s9"><title>5. 结论</title><p>本研究结果显示：宫颈鳞癌患者及组织分化较低的患者对NACT更为敏感；NACT可以提高局部晚期患者的远期生存率；NACT有效者可延长LACC患者的总生存期和无瘤生存期。在临床实践中，我们仍需进行高质量的临床证据支持NACT的应用疗效，规范治疗模式并根据患者的病情进行个体化治疗方案的选择。</p></sec><sec id="s10"><title>文章引用</title><p>郭 宁,李贝贝,黄利英,王 蓁,蒋长青. 新辅助化疗对194例局部晚期宫颈癌患者疗效观察及预后分析The Effect of Neoadjuvant Chemotherapy in 194 Patients with Locally Advanced Cervical Cancer and Prognostic Analysis[J]. 临床医学进展, 2020, 10(09): 2087-2094. https://doi.org/10.12677/ACM.2020.109313</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37765-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Song, B., Ding, C., Chen, W., et al. (2017) Incidence and Mortality of Cervical Cancer in China, 2013. Chinese Journal of Cancer Research, 29, 471-476.</mixed-citation></ref><ref id="hanspub.37765-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Koh, W.J., Abu-Rustum, N.R., Bean, S. and Bradley, K. (2019) Cervical Cancer, Version 3. 2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17, 64-84.</mixed-citation></ref><ref id="hanspub.37765-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kong, S.Y., Huang, K.C., Zeng, C., Ma, X.Y. and Wang, S.X. (2018) The Association between Short-Term Response And Long-Term Survival for Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy: A System Review And Meta-Analysis. Scientific Reports, 8, Article No. 1545. &lt;br&gt;https://doi.org/10.1038/s41598-018-19948-0</mixed-citation></ref><ref id="hanspub.37765-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">谢幸, 孔北华, 段涛. 妇产科学[M]. 第9版. 北京: 人民卫生出版社, 2018: 300.</mixed-citation></ref><ref id="hanspub.37765-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">柳影, 程颖. 实体肿瘤疗效评价标准的研究[J]. 实用肿瘤学杂志, 2004(2): 149-152.</mixed-citation></ref><ref id="hanspub.37765-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">雷叶青, 李海涛, 许金凤, 等. 紫杉醇脂质体联合奈达铂新辅助化疗治疗局部晚期宫颈癌的近期疗效观察[J]. 现代诊断与治疗, 2016, 27(11): 2053-2055.</mixed-citation></ref><ref id="hanspub.37765-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gupta, S., Maheshwari, A., Parab, P., et al. (2018) Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients with Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 36, 1548-1555.  
&lt;br&gt;https://doi.org/10.1200/JCO.2017.75.9985</mixed-citation></ref><ref id="hanspub.37765-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Matsuo, K., Shimada, M., Yamaguchi, S., et al. (2019) Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival. Journal of Clinical Medicine, 8, 156. &lt;br&gt;https://doi.org/10.3390/jcm8020156</mixed-citation></ref><ref id="hanspub.37765-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">He, L., Wu, L., Su, G., Wei, W., et al. (2014) The Efficacy of Neoadjuvant Chemotherapy in Different Histological Types of Cervical Cancer. Gynecologic Oncology, 134, 419-425.</mixed-citation></ref><ref id="hanspub.37765-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Qin, T., Zhen, J., Zhou, M., et al. (2016) Efficacy of Neoadjuvant Chemotherapy plus Radical Surgery in Patients with Bulky Stage II Cervical Squamous Cell Carcinoma: A Retrospective Cohort Study. International Journal of Surgery, 30, 121-125. &lt;br&gt;https://doi.org/10.1016/j.ijsu.2016.04.038</mixed-citation></ref><ref id="hanspub.37765-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">陈春林, 李朋飞. 从中国宫颈癌真实世界研究临床大数据看宫颈癌术前化疗存在的问题和对策[J]. 中国实用妇科与产科杂志, 2018, 34(11): 1185-1189.</mixed-citation></ref><ref id="hanspub.37765-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yin, M., Zhao, F., Lou, G., et al. (2011) The Long-Term Efficacy of Neoadjuvant Chemotherapy Followed by Radical Hysterectomy Compared with Radical Surgery Alone or Concurrent Chemoradiotherapy on Locally Advanced-Stage Cervical Cancer. International Journal of Gynecological Cancer, 21, 92-99.</mixed-citation></ref><ref id="hanspub.37765-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J., Kim, T.H., Kim, G.E., Keum, K.C. and Kim, Y.B. (2016) Neoadjuvant Chemotherapy Followed by Surgery Has No Therapeutic Advantages over Concurrent Chemoradio-Therapy in International Federation of Gynecology and Obstetrics Stage IB-IIB Cervical Cancer. Journal of Gynecologic Oncology, 27, e52. 
&lt;br&gt;https://doi.org/10.3802/jgo.2016.27.e52</mixed-citation></ref><ref id="hanspub.37765-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, H., He, Y., Yang, S.L., Zhao, Q. and Wu, Y.M. (2019) Neoadjuvant Chemotherapy with Radical Surgery vs Radical Surgery Alone for Cervical Cancer: A Systematic Review and Meta-Analysis. OncoTargets and Therapy, 12, 1881-1891. &lt;br&gt;https://doi.org/10.2147/OTT.S186451</mixed-citation></ref><ref id="hanspub.37765-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Katsumata, N., Yoshikawa, H., Kobayashi, H., et al. (2013) Phase III Randomised Controlled Trial of Neoadjuvant Chemotherapy plus Radical Surgery vs Radical Surgery alone for stages IB2, IIA2, and IIB Cervical Cancer: A Japan Clinical Oncology Group Trial (JCOG 0102). British Journal of Cancer, 108, 1957-1963. 
&lt;br&gt;https://doi.org/10.1038/bjc.2013.179</mixed-citation></ref><ref id="hanspub.37765-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kong, S.Y., Huang, K., Zeng, C., Ma. X.Y. and Wang, S.X. (2018) The Association between Short-Term Response and Long-Term Survival for Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy: A System Review and Meta-Analysis. Scientific Reports, 8, 1545-1553. &lt;br&gt;https://doi.org/10.1038/s41598-018-19948-0</mixed-citation></ref><ref id="hanspub.37765-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Yang, L., Guo, J., Shen, Y., et al. (2015) Clinical Efficacy and Safety of Paclitaxel plus Carboplatin as Neoadjuvant Chemotherapy Prior to Radical Hysterectomy and Pelvic Lymphadenectomy for Stage IB2-IIB Cervical Cancer. International Journal of Clinical and Experimental Medicine, 8, 13690-13698.</mixed-citation></ref><ref id="hanspub.37765-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">邹婷婷, 郑春莹, 张志邦, 余立, 符淳. 187例I B2和IIA2期宫颈癌新辅助化疗疗效及预后的影响因素[J]. 中南大学学报(医学版), 2020, 45(3): 297-304.</mixed-citation></ref></ref-list></back></article>